Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 71.28 USD 0.32% Market Closed
Market Cap: 11.3B USD
Have any thoughts about
Bio-Techne Corp?
Write Note

Bio-Techne Corp
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bio-Techne Corp
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Bio-Techne Corp
NASDAQ:TECH
Other Current Assets
$43.4m
CAGR 3-Years
37%
CAGR 5-Years
19%
CAGR 10-Years
14%
Thermo Fisher Scientific Inc
NYSE:TMO
Other Current Assets
$1.9B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Other Current Assets
$658m
CAGR 3-Years
-18%
CAGR 5-Years
4%
CAGR 10-Years
1%
Mettler-Toledo International Inc
NYSE:MTD
Other Current Assets
$113.6m
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
0%
Agilent Technologies Inc
NYSE:A
Other Current Assets
$272m
CAGR 3-Years
1%
CAGR 5-Years
9%
CAGR 10-Years
-5%
IQVIA Holdings Inc
NYSE:IQV
Other Current Assets
$670m
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
16%
No Stocks Found

Bio-Techne Corp
Glance View

Market Cap
11.3B USD
Industry
Life Sciences Tools & Services

Bio-Techne Corp. stands at the forefront of scientific progress, intertwining innovation with essential biotechnology solutions. Founded in 1976 and headquartered in Minneapolis, the company has evolved from its roots in producing protein research reagents to a diversified powerhouse, supporting the life sciences and clinical diagnostics sectors. Bio-Techne's expansive portfolio encompasses cutting-edge tools and technologies allowing researchers to delve deeper into cellular analysis, gene expression, and molecular diagnostics. With brands like R&D Systems, Novus Biologicals, and ProteinSimple under its belt, the company empowers scientists worldwide to unlock new discoveries, simulate complex biological processes, and ultimately contribute to advancements in healthcare and life sciences. For investors, Bio-Techne presents a compelling opportunity as it operates in a rapidly growing market fueled by increasing demand for precision medicine and advanced research capabilities. The company has demonstrated robust financial performance, marked by consistent revenue growth and healthy profit margins, driven by its commitment to research and development. As Bio-Techne continues to expand its product offerings and enhance its technological capabilities through strategic acquisitions, it stands poised to capture greater market share and drive shareholder value. With a seasoned management team guided by a focus on innovation and customer-centric solutions, Bio-Techne is not just responding to market trends but actively shaping the future of biotechnology.

TECH Intrinsic Value
54.19 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Bio-Techne Corp's Other Current Assets?
Other Current Assets
43.4m USD

Based on the financial report for Jun 30, 2024, Bio-Techne Corp's Other Current Assets amounts to 43.4m USD.

What is Bio-Techne Corp's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
14%

Over the last year, the Other Current Assets growth was 60%. The average annual Other Current Assets growth rates for Bio-Techne Corp have been 37% over the past three years , 19% over the past five years , and 14% over the past ten years .

Back to Top